CAR T-Cell Therapy for Non-Hodgkin Lymphoma
The chief of oncology and hematology at University of Nebraska Medical Center discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Julie M. Vose, MD, MBA, about the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL). Vose is the Neumann M. and Mildred E. Harris Professor and chief of Oncology and Hematology in the Department of Internal Medicine at University of Nebraska Medical Center.
CAR T-cell therapies are being investigated for use in several subtypes of NHL in ongoing clinical trials. The therapies are currently indicated for use in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), as well as mantle cell lymphoma (MCL).
For example, trials are investigating CAR T-cell therapy in follicular lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Additionally, other products beyond those FDA approved are being tested in DLBCL and MCL, Vose concludes.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
